KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Accounts Payables (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Accounts Payables for 16 consecutive years, with $115.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 30.88% year-over-year to $115.7 million, compared with a TTM value of $115.7 million through Dec 2025, up 30.88%, and an annual FY2025 reading of $115.7 million, up 30.88% over the prior year.
  • Accounts Payables was $115.7 million for Q4 2025 at Alnylam Pharmaceuticals, down from $117.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $117.6 million in Q3 2025 and bottomed at $40.0 million in Q3 2021.
  • Average Accounts Payables over 5 years is $72.7 million, with a median of $72.1 million recorded in 2021.
  • The sharpest move saw Accounts Payables soared 103.17% in 2021, then plummeted 43.4% in 2023.
  • Year by year, Accounts Payables stood at $73.4 million in 2021, then surged by 33.6% to $98.1 million in 2022, then plummeted by 43.4% to $55.5 million in 2023, then surged by 59.25% to $88.4 million in 2024, then surged by 30.88% to $115.7 million in 2025.
  • Business Quant data shows Accounts Payables for ALNY at $115.7 million in Q4 2025, $117.6 million in Q3 2025, and $102.4 million in Q2 2025.